efficacy of alfacalcidol on peg-ifn/ ribavirin combination therapy for elderly patients with chronic hepatitis c: a pilot study
نویسندگان
چکیده
patients and methods consecutive twenty chc patients aged ≥ 65 years were enrolled in this pilot study. fifteen patients met the inclusion criteria and received peg-ifn/ ribavirin therapy combined with alfacalcidol. four-week lead-in of oral alfacalcidol was conducted, and it was subsequently and concurrently administered in peg-ifn/ ribavirin combination therapy (vitamin d group). age, gender, and il28b genotype-matched patients, who received peg-ifn/ ribavirin alone, were saved as control group (n = 15) to compare the treatment outcome with the vitamin d group. results subjects consisted of 14 males and 16 females, with a median age of 70 years (65-78). the serum 25 (oh) d3 concentration in females (20 ng/ml, 11-37) was significantly lower than males (27 ng/ml, 13-49) (p = 0.004). sustained virological response (svr) rates were 33.3% (5/15) in the control group and 80.0% (12/15) in the vitamin d group, respectively (p = 0.025). while no significant difference was shown in the (svr) rate between the two groups among males (p = 0.592), in females the svr rate was significantly higher in the vitamin d group (87.5%, 7/8) than the control group (25.0%, 2/8) (p = 0.041). the relapse rates in the groups with and without alfacalcidol were 7.7% (1/13) and 61.5% (8/13), respectively (p = 0.011). interestingly, in females, the relapse in the control group was shown in 5 of 7 (71.4%), whereas in the vitamin d group the relapse rate was decreased (1/8, 12.5%) (p = 0.041). no specific adverse events were observed in the vitamin d group. background serum vitamin d concentration is reported to show a decrease in older age. patients with chronic hepatitis c (chc) in japan are older on average than those in western countries. moreover, the outcome of pegylated-interferon (peg-ifn)/ ribavirin therapy combined with vitamin d in elderly patients is unclear. conclusions peg-ifn/ ribavirin combined with alfacalcidol may be effective and safe in elderly chc patients. in particular, concomitant administration of alfacalcidol may lead to a reduced relapse rate, and consequently improving the svr rate in elderly females. objectives this pilot study explored the efficacy and safety of alfacalcidol as vitamin d source in peg-ifn/ ribavirin combination therapy for elderly chc patients infected with hepatitis c virus genotype 1b.
منابع مشابه
Efficacy of Alfacalcidol on PEG-IFN/ Ribavirin Combination Therapy for Elderly Patients With Chronic Hepatitis C: A Pilot Study
BACKGROUND Serum vitamin D concentration is reported to show a decrease in older age. Patients with chronic hepatitis C (CHC) in Japan are older on average than those in Western countries. Moreover, the outcome of pegylated-interferon (PEG-IFN)/ ribavirin therapy combined with vitamin D in elderly patients is unclear. OBJECTIVES This pilot study explored the efficacy and safety of alfacalcido...
متن کاملEFFICACY AND SAFETY OF COMBINATION THERAPY OF INTERFERON-ALPHA 2B PLUS RIBAVIRIN FOR CHRONIC HEPATITIS C
Introduction: The aim of this study is to assess the therapeutic efficacy and safety of a particular brand of IFN alpha (PDferon B®) in combination with ribavirin (RlBA) on Iranian patients with chronic hepatitis C (CHC). The addition of RIBA to the standard treatment with interferon (IFN) alpha led to an improvement in sustained virologic response (SVR) from less than 20% with IFN monother...
متن کاملA MULTICENTER STUDY TO EVALUATE THE SAFETY AND EFFICACY OF HEBER ON (INTERFERON ALFA-2b) IN COMBINATION WITH RIBAVIRIN FOR THE TREATMENT OF CHRONIC HEPATITIS C IN IRAN
ABSTRACT Background: Combination therapy with interferon and ribavirin is the most effective treatment for chronic hepatitis C today. The aim of this study was to evaluate the efficacy and safety of thrice-weekly Heberon (interferon alfa-2b) in combination with ribavirin as first -line treatment of chronic hepatitis C. Methods: A total of97 treatment-naive patients received Heberon three milli...
متن کاملEfficacy of Prolonged Treatment With Pegylated Interferon (Peg-IFN) and Ribavirin in Thalassemic Patients With Hepatitis C Who Relapsed After Previous Peg-IFN-Based Therapy
BACKGROUND Most thalassemic patients with chronic hepatitis C virus (HCV) infection do not respond to therapy with pegylated interferon (Peg-IFN) plus ribavirin (RBV) due to hepatic siderosis and RBV dose reduction caused by RBV-induced anemia. OBJECTIVES In the present study, we recruited HCV genotype 1-infected thalassemic patients who had relapsed after a 48-week treatment with Peg-IFN plu...
متن کاملefficacy of prolonged treatment with pegylated interferon (peg-ifn) and ribavirin in thalassemic patients with hepatitis c who relapsed after previous peg-ifn-based therapy
background most thalassemic patients with chronic hepatitis c virus (hcv) infection do not respond to therapy with pegylated interferon (peg-ifn) plus ribavirin (rbv) due to hepatic siderosis and rbv dose reduction caused by rbv-induced anemia. objectives in the present study, we recruited hcv genotype 1-infected thalassemic patients who had relapsed after a 48-week treatment with peg-ifn plus ...
متن کاملefficacy and safety of combination therapy of interferon-alpha 2b plus ribavirin for chronic hepatitis c
introduction: the aim of this study is to assess the therapeutic efficacy and safety of a particular brand of ifn alpha (pdferon b®) in combination with ribavirin (rlba) on iranian patients with chronic hepatitis c (chc). the addition of riba to the standard treatment with interferon (ifn) alpha led to an improvement in sustained virologic response (svr) from less than 20% with ifn monotherapy ...
متن کاملمنابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
hepatitis monthlyجلد ۱۳، شماره ۱۲، صفحات ۰-۰
میزبانی شده توسط پلتفرم ابری doprax.com
copyright © 2015-2023